Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor Samples
Status:
Not yet recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, single-center, open-label phase II study designed to assess the
efficacy of surufatinib in participants with advanced hepatocellular carcinoma based on
single-cell sequencing of tumor samples.
Phase:
Phase 2
Details
Lead Sponsor:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School